-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the Jilin Provincial Public Resources Trading Center issued a notice on the formal negotiation of the third batch of Zhongcheng medicines for the centralized procurement of medicines by medical institutions in Jilin Province in 2021
.
According to the notice, the negotiation involves 320 batches of proprietary Chinese medicines, of which 92 are capsules.
The products included in the list are Jianweixiaoshi Tablets, Baohe Pills, Xiaoer Kechuanling Oral Liquid, Strong Loquat Loquat, Commonly used medicines such as Ganmaoling granules
.
It is understood that this is another centralized procurement of Chinese patent medicines after Guangdong announced two days ago to start the collection of Chinese patent medicine alliances in 7 provinces
.
On September 14, the Guangdong Provincial Drug Trading Center issued a notice on soliciting opinions on the "Guangdong Union Qingkailing and other 58 drug groups' procurement documents (draft for comments)"
.
All the dosage forms and specifications of 58 generic drugs in the list of basic medical insurance drugs with large dosage and high purchase amount were also included in this centralized procurement
.
Among them, there are also large varieties such as Xiyanping, Lianhua Qingwen, and Xiaoer Lianqiao Qingre that have sold more than 100 million yuan, as well as common medicines such as Qingkailing, antiviral oral liquid, and orange red phlegm and cough
.
According to analysis, in fact, in addition to the above-mentioned provinces, Qinghai Province, Zhejiang Jinhua, Henan Puyang and other places have also carried out centralized procurement exploration for some varieties of Chinese patent medicines with high demand and high amounts
.
In this regard, industry analysts believe that more and more provinces and cities are currently exploring pilot projects for centralized procurement of Chinese patent medicines, mainly because they are influenced by national policies
.
As early as January 28, 2021, the "Opinions of the General Office of the State Council on Promoting the Normalized and Institutionalized Development of Centralized Drug Purchases" (hereinafter referred to as the "Opinions") clearly stated that "exploration of similar indications or functions and indications" The merging of different generic drugs to carry out centralized and volume procurement" provides basic compliance for the centralized procurement of proprietary Chinese medicines
.
In addition, in August this year, the National Medical Insurance Administration made it clear that it would start with high-priced and large-volume varieties, scientifically and steadily promote the reform of centralized procurement of proprietary Chinese medicines and formula particles, and further accelerated the procurement of proprietary Chinese medicines
.
The industry predicts that in the future, in the context of more and more provinces exploring the centralized procurement of Chinese patent medicines, the national procurement of Chinese patent medicines is expected to be only a matter of time.
.
Then, under the background that the centralized procurement of Chinese patent medicines is blooming all over the country, and the pace of national procurement continues to approach, how will the industry and enterprises be affected? The analysis believes that the entire Chinese patent medicine industry may face a reshuffle in the future, and a batch of products with a smaller market scale and no special formulations may be eliminated
.
It is understood that compared with 2019, the market share of proprietary Chinese medicines has clearly shown a downward trend, and the future decline will be even worse
.
Therefore, for Chinese medicine companies, with the continuous advancement of centralized procurement, they need to seek innovation and transformation in order to survive
.
The industry believes that in the future, only by following the law of traditional Chinese medicine development, inheriting the essence, and keeping up with innovation, can we accelerate the modernization and industrialization of Chinese medicine, truly face the frontiers of world science and technology, and face the main economic battlefield.
More development opportunities
.
.
According to the notice, the negotiation involves 320 batches of proprietary Chinese medicines, of which 92 are capsules.
The products included in the list are Jianweixiaoshi Tablets, Baohe Pills, Xiaoer Kechuanling Oral Liquid, Strong Loquat Loquat, Commonly used medicines such as Ganmaoling granules
.
It is understood that this is another centralized procurement of Chinese patent medicines after Guangdong announced two days ago to start the collection of Chinese patent medicine alliances in 7 provinces
.
On September 14, the Guangdong Provincial Drug Trading Center issued a notice on soliciting opinions on the "Guangdong Union Qingkailing and other 58 drug groups' procurement documents (draft for comments)"
.
All the dosage forms and specifications of 58 generic drugs in the list of basic medical insurance drugs with large dosage and high purchase amount were also included in this centralized procurement
.
Among them, there are also large varieties such as Xiyanping, Lianhua Qingwen, and Xiaoer Lianqiao Qingre that have sold more than 100 million yuan, as well as common medicines such as Qingkailing, antiviral oral liquid, and orange red phlegm and cough
.
According to analysis, in fact, in addition to the above-mentioned provinces, Qinghai Province, Zhejiang Jinhua, Henan Puyang and other places have also carried out centralized procurement exploration for some varieties of Chinese patent medicines with high demand and high amounts
.
In this regard, industry analysts believe that more and more provinces and cities are currently exploring pilot projects for centralized procurement of Chinese patent medicines, mainly because they are influenced by national policies
.
As early as January 28, 2021, the "Opinions of the General Office of the State Council on Promoting the Normalized and Institutionalized Development of Centralized Drug Purchases" (hereinafter referred to as the "Opinions") clearly stated that "exploration of similar indications or functions and indications" The merging of different generic drugs to carry out centralized and volume procurement" provides basic compliance for the centralized procurement of proprietary Chinese medicines
.
In addition, in August this year, the National Medical Insurance Administration made it clear that it would start with high-priced and large-volume varieties, scientifically and steadily promote the reform of centralized procurement of proprietary Chinese medicines and formula particles, and further accelerated the procurement of proprietary Chinese medicines
.
The industry predicts that in the future, in the context of more and more provinces exploring the centralized procurement of Chinese patent medicines, the national procurement of Chinese patent medicines is expected to be only a matter of time.
.
Then, under the background that the centralized procurement of Chinese patent medicines is blooming all over the country, and the pace of national procurement continues to approach, how will the industry and enterprises be affected? The analysis believes that the entire Chinese patent medicine industry may face a reshuffle in the future, and a batch of products with a smaller market scale and no special formulations may be eliminated
.
It is understood that compared with 2019, the market share of proprietary Chinese medicines has clearly shown a downward trend, and the future decline will be even worse
.
Therefore, for Chinese medicine companies, with the continuous advancement of centralized procurement, they need to seek innovation and transformation in order to survive
.
The industry believes that in the future, only by following the law of traditional Chinese medicine development, inheriting the essence, and keeping up with innovation, can we accelerate the modernization and industrialization of Chinese medicine, truly face the frontiers of world science and technology, and face the main economic battlefield.
More development opportunities
.
